Key Laboratory of Clinical in Vitro Diagnostic Techniques of Zhejiang Province
Key Laboratory of Clinical in Vitro Diagnostic Techniques of Zhejiang Province (CIVD) is constructed with the support of Department of Laboratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University which is the first batch of National Key Specialty. Yu Chen, the National “Ten Thousand Talents Program” Leading Scientist, is positioned as director of the laboratory. Research team of CIVD includes about 50 M.D., Ph.D. and senior-title scientists. Professor Honglin Chen from the University of Hong Kong, Professor Gongxiang Chen who is National “Thousand Talents Program” Leading Scientist and other scientists are engaged as principle investigators. Since the establishment of CIVD, lab research team has been undertaking 45 projects including National Science and Technology Major Project of the Ministry of Science and Technology of China, National Program on Key Basic Research Project of China (973 Program) and National High-tech R&D Program of China (863 Program) and provincial projects. Under the leadership of Director Chen, the team has published 200 SCI papers, obtained 24 National invention patents and won 6 awards including the first prize of Natural Science Award of Zhejiang Province and the second prize of State Technological Invention Award. CIVD built up a bridge between domestic and international laboratories and carried out broad cooperation. In 2019, Institute of Laboratory Medicine, Zhejiang University was established with the support of CIVD and was successfully selected as a branch of the National Medical Research Center (Laboratory Medicine). During COVID-19 period, Director Chen, as a member of expert group, actively participated in epidemic prevention and control as well as the formulation of COVID-19 diagnosis and treatment strategy. He also organized laboratory testing and biosafety training for the whole country and Zhejiang province many times, and dispatched technical backbones to assist Italy and Wuhan for controlling COVID-19.